» Articles » PMID: 25193652

Prognostic Value of Volumetric Parameters of (18)F-FDG PET in Non-small-cell Lung Cancer: a Meta-analysis

Overview
Date 2014 Sep 7
PMID 25193652
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We conducted a comprehensive systematic review of the literature on volumetric parameters from (18)F-FDG PET and a meta-analysis of the prognostic value of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) in patients with lung cancer.

Methods: A systematic search of MEDLINE and EMBASE was performed using the keywords "positron emission tomography (PET)", "lung cancer", and "volume". Inclusion criteria were: (18)F-FDG PET used as an initial imaging tool; studies limited to non-small-cell lung cancer (NSCLC); volume measurement of lung cancer; patients who had not undergone surgery, chemotherapy, or radiotherapy before the PET scan; and studies that reported survival data. Event-free survival and overall survival were evaluated as outcomes. The impact of MTV and TLG on survival was measured in terms of the hazard ratio (HR) effect size. Data from each study were analysed using Review Manager 5.2.

Results: Thirteen eligible studies including 1,581 patients were analysed. Patients with high MTV showed a worse prognosis with an HR of 2.71 (95% CI 1.82 - 4.02, p < 0.00001) for adverse events and an HR of 2.31 (95% CI 1.54 - 3.47, p < 0.00001) for death. Patients with high TLG also showed a worse prognosis with an HR of 2.35 (95% CI 1.91 - 2.89, p < 0.00001) for adverse events and an HR of 2.43 (95% CI 1.89 - 3.11, p < 0.00001) for death. The prognostic value of MTV and TLG remained significant in a subgroup analysis according to TNM stage as well as the methods for defining cut-off values and tumour delineation.

Conclusion: Volumetric parameters from (18)F-FDG PET are significant prognostic factors for outcome in patients with NSCLC. Patients with a high MTV or TLG are at higher risk of adverse events and death. MTV and TLG were significant prognostic factors in patients with TNM stage I/II and stage III/IV NSCLC.

Citing Articles

PET-Assessed Metabolic Tumor Volume Across the Spectrum of Solid-Organ Malignancies: A Review of the Literature.

Agarwal A, Wehrle C, Satish S, Mahajan P, Kamath S, Koyfman S Biomedicines. 2025; 13(1).

PMID: 39857707 PMC: 11762135. DOI: 10.3390/biomedicines13010123.


Prognostic value of metabolic tumor volume on [F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer.

Brose A, Miederer I, Konig J, Gkika E, Sahlmann J, Schimek-Jasch T Cancer Imaging. 2024; 24(1):171.

PMID: 39709461 PMC: 11662478. DOI: 10.1186/s40644-024-00811-7.


The role of baseline F-FDG PET/CT for survival prognosis in NSCLC patients undergoing immunotherapy: a systematic review and meta-analysis.

Huang M, Zou Y, Wang W, Li Q, Tian R Ther Adv Med Oncol. 2024; 16:17588359241293364.

PMID: 39502406 PMC: 11536524. DOI: 10.1177/17588359241293364.


Predictive value of metabolic parameters and apparent diffusion coefficient derived from 18F-FDG PET/MR in patients with non-small cell lung cancer.

Jiang H, Li Z, Meng N, Luo Y, Feng P, Fu F BMC Med Imaging. 2024; 24(1):290.

PMID: 39472782 PMC: 11523797. DOI: 10.1186/s12880-024-01445-8.


Prognostic significance of pretreatment PET parameters in inoperable, node-positive NSCLC patients with poor prognostic factors undergoing hypofractionated radiotherapy: a single-institution retrospective study.

Zinn A, Kenndoff S, Holzgreve A, Kasmann L, Guggenberger J, Hering S EJNMMI Rep. 2024; 8(1):32.

PMID: 39375264 PMC: 11458843. DOI: 10.1186/s41824-024-00220-w.


References
1.
Yoo S, Kim J, Chong A, Kwon S, Min J, Song H . Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer. Nucl Med Mol Imaging. 2014; 46(4):286-93. PMC: 4043070. DOI: 10.1007/s13139-012-0165-5. View

2.
Budiawan H, Cheon G, Im H, Lee S, Paeng J, Kang K . Heterogeneity Analysis of (18)F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting. Nucl Med Mol Imaging. 2014; 47(4):232-41. PMC: 4035177. DOI: 10.1007/s13139-013-0216-6. View

3.
Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J . Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cancer. 2012; 132(2):E37-47. DOI: 10.1002/ijc.27779. View

4.
Zhang L, Wang Y, Lei J, Tian J, Zhai Y . Dual time point 18FDG-PET/CT versus single time point 18FDG-PET/CT for the differential diagnosis of pulmonary nodules: a meta-analysis. Acta Radiol. 2013; 54(7):770-7. DOI: 10.1177/0284185113481594. View

5.
Kim K, Kim S, Kim I, Kim Y, Pak K, Kim H . Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012; 33(6):613-20. DOI: 10.1097/MNM.0b013e328351d4f5. View